Europe • Frankfurt Stock Exchange • FRA:IDP • US09062X1037
IDP gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 85 industry peers in the Biotechnology industry. IDP gets an excellent profitability rating and is at the same time showing great financial health properties. IDP is cheap, but on the other hand it scores bad on growth. These ratings could make IDP a good candidate for value investing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.3 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.66 | ||
| Fwd PE | 11.55 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.57 | ||
| EV/EBITDA | 7.74 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ChartMill assigns a fundamental rating of 6 / 10 to IDP.DE.
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
BIOGEN INC (IDP.DE) has a profitability rating of 7 / 10.
The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -7.36% in the next year.